DeepMed Research

ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Protective Measures Against SARS-CoV-2 Contamination of Young Healthy Volunteers During a Concert of Actual Music

Not Applicable

Withdrawn

Conditions: Corona Virus Infection

Interventions: Other: Assisting to the event

First Posted Date: 2021-05-03

Last Posted Date: 2021-12-30

Lead Sponsor: ANRS, Emerging Infectious Diseases

Registration Number: NCT04868942

Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week

Phase 3

Conditions: HIV Infections

Interventions: Drug: ARV bitherapie

First Posted Date: 2021-04-30

Last Posted Date: 2021-11-08

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 440

Registration Number: NCT04867083

Locations: 🇫🇷
Centre hospitalier Victor Dupouy/Service d'Hématologie-Unité d'Immunologie, Argenteuil Cedex, France
🇫🇷
Hôpital Louis Pasteur/Service des Maladies Infectieuses, Chartres, Le Coudray, France
🇫🇷
Centre hospitalier de Poissy/Service des Maladies Infectieuses, Poissy, France

and more 35 locations

Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Interventions: Other: Data collection

First Posted Date: 2021-04-28

Last Posted Date: 2021-04-28

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 2200

Registration Number: NCT04863547

Locations: 🇫🇷
CHU Amiens Picardie Site Nord, Amiens, France
🇫🇷
hôpital Avicenne, Bobigny, France
🇫🇷
Centre hospitalier métropole Savoie, Chambéry, France

and more 49 locations

National Survey About Trajectory and Life Conditions of HIV Trans People in France

Completed

Conditions: HIV Seropositivity

Interventions: Other: Questionnaire

First Posted Date: 2021-04-19

Last Posted Date: 2024-02-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 536

Registration Number: NCT04849767

Locations: 🇫🇷
INSERM, Marseille, France

A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Phase 1

Active, not recruiting

Conditions: Healthy Adults

Interventions: Biological: Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L
Biological: DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)
Biological: DNA-HIV-PT123 4mg and CN54gp140/MPLA-L

First Posted Date: 2021-04-14

Last Posted Date: 2024-01-03

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 68

Registration Number: NCT04844775

Locations: 🇫🇷
Hôpital Henri Mondor, Créteil, Paris, France
🇫🇷
CIC Cochin, Paris, Paris Cedex 14, France
🇨🇭
CHUV, Lausanne, Vaud, Switzerland

and more 1 locations

Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Biological: Solo 0.3 group
Biological: Late boost CD40 alone
Biological: Solo 1 group
Biological: Late boost CD40 adjuvanted
Biological: Solo 3 group
Biological: Combi 0.3 group
Biological: Combi 1 group
Biological: Combi 3 group

First Posted Date: 2021-04-13

Last Posted Date: 2024-12-17

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 72

Registration Number: NCT04842682

Locations: 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷
CIC 1417 - Hôpital Cochin, Paris, France
🇨🇭
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers

Phase 2

Completed

Conditions: Healthy
Immunization; Infection

Interventions: Biological: 3 doses of BNT162b2 vaccine
Biological: 2 dose of BNT162b2 vaccine

First Posted Date: 2021-04-01

Last Posted Date: 2023-12-14

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 267

Registration Number: NCT04824638

Locations: 🇫🇷
Centre de Recherche Clinique, CHU Côte de Nacre, Caen, France
🇫🇷
Service des maladies infectieuses, CHU de Caremeau, Nîmes, France
🇫🇷
CIC1417, hôpital Cochin, Paris, France

and more 8 locations

Covid-19 Vaccine Cohort in Specific Populations

Conditions: Immune Deficiency

Interventions: Biological: COVID-19 vaccine

First Posted Date: 2021-04-01

Last Posted Date: 2022-02-04

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 6920

Registration Number: NCT04824651

Locations: 🇫🇷
Cmg-Ec U1219, Bordeaux, France
🇫🇷
Paris Cochin APHP, Paris, France
🇫🇷
Nîmes CHU, Nîmes, France

Prophylaxis Vaccine Antibodies Ebola

Phase 2

Conditions: Ebola Virus Disease

Interventions: Drug: ansuvimab
Biological: Ervebo

First Posted Date: 2021-03-30

Last Posted Date: 2021-10-15

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 250

Registration Number: NCT04822376

Locations: 🇬🇳
Centre de Traitement Ebola de N'Zerekore, N'Zerekore, Guinea

Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

Phase 3

Active, not recruiting

Conditions: HIV-1-infection
Immuno-Deficiency
Tuberculosis

Interventions: Drug: Intensified TB treatment (initial phase)
Drug: WHO standard TB treatment (initial phase)

First Posted Date: 2021-02-04

Last Posted Date: 2025-02-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 1330

Registration Number: NCT04738812

Locations: 🇰🇭
National Center for HIV/AIDS, Dermatology and STD (NCHADS), Phnom Penh, Cambodia
🇨🇲
Jamot Hospital, Yaoundé, Cameroon
🇬🇳
Ignace Deen Hospital, Conakry, Guinea

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy